Condition-specific dosing for XARELTO®
Available Strengths
Tablets not shown to actual size.
Condition-specific dosing for XARELTO®
Dosing Guide
The complete guide to dosing for XARELTO®
Prescribing Information
Full Prescribing Information for XARELTO®
NVAF
NVAF: Reducing stroke risk
20 mg once daily with the evening meal in patients with a CrCl >50 mL/min
15 mg moderate-to-severe renal impairment dose
Once daily with the evening meal in patients with a CrCl ≤50 mL/min
Renal Dosing Considerations
Periodically assess renal function as clinically indicated (ie, more frequently in situations in which renal function may decline) and adjust therapy accordingly. Consider dose adjustment or discontinuation of XARELTO® in patients who develop acute renal failure while on XARELTO®
See section 8.6 of the Prescribing Information for additional information
CAD/PAD
CAD: Reducing the risk of major CV events
PAD: Reducing the risk of major thrombotic vascular events, including patients after LER due to symptomatic PAD
2.5 mg twice daily, with or without food, in combination with aspirin (75 mg-100 mg) once daily
No dose adjustment needed based on CrCl
When starting therapy after a successful LER procedure, initiate once hemostasis has been established
DVT/PE:
DVT treatment
For the first 21 days, 15 mg twice daily with food, at the same time each day in patients with a CrCl ≥15 mL/min
Starting at day 22, change to 20 mg once daily with food, at the same time each day, for remaining treatment in patients with a CrCl ≥15 mL/min
Avoid use in patients with CrCl <15 mL/min
PE treatment
For the first 21 days, 15 mg twice daily with food, at the same time each day in patients with a CrCl ≥15 mL/min
Starting at day 22, change to 20 mg once daily with food, at the same time each day, for remaining treatment in patients with a CrCl ≥15 mL/min
Avoid use in patients with CrCl <15 mL/min
DVT/PE:
Reduction in the risk of recurrence
10 mg once daily with or without food after ≥6 months of standard anticoagulant treatment in patients with a CrCl ≥15 mL/min
Avoid use in patients with CrCl <15 mL/min
DVT PROPHYLAXIS:
After hip replacement surgery
10 mg once daily for 35 days, 6 to 10 hours after surgery once hemostasis has been established, with or without food, in patients with a CrCl ≥15 mL/min
Avoid use in patients with CrCl <15 mL/min
DVT PROPHYLAXIS:
After knee replacement surgery
10 mg daily for 12 days, 6 to 10 hours after surgery once hemostasis has been established, with or without food, in patients with a CrCl ≥15 mL/min
Avoid use in patients with CrCl <15 mL/min
VTE PROPHYLAXIS:
Acutely ill medical patients◇
10 mg once daily, in hospital and after hospital discharge, for a total recommended duration of 31 to 39 days, with or without food, in patients with a CrCl ≥15 mL/min
Avoid use in patients with CrCl <15 mL/min